Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14521117 | 0.89 | MDM2 (0.62) | MDM2NPC1MAPTFLT3TLK2 | |
| SCHEMBL14521137 | 0.84 | NPC1 (0.61) | MDM2NPC1MAPTFLT3TLK2 | |
| SCHEMBL14521129 | 0.83 | MDM2 (0.56) | MDM2NPC1MAPTFLT3TLK2 | |
| SCHEMBL14521115 | 0.83 | MDM2 (0.63) | MDM2NPC1LMNAMAPTRAB9A | |
| SCHEMBL14521142 | 0.82 | MEN1 (0.57) | MDM2NPC1FLT3TLK2MEN1 | |
| SCHEMBL14521166 | 0.82 | MDM2 (0.54) | MDM2NPC1MAPTFLT3TLK2 | |
| SCHEMBL14521151 | 0.82 | MDM2 (0.54) | MDM2NPC1MAPTFLT3TLK2 | |
| SCHEMBL14521148 | 0.81 | PLK4 (0.61) | MDM2NPC1FLT3TLK2RET | |
| SCHEMBL14521134 | 0.81 | MDM2 (0.53) | MDM2NPC1MAPTFLT3TLK2 | |
| SCHEMBL14674453 | 0.81 | MDM2 (0.55) | MDM2TGM2NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088051-A1 | INDOLINONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| US-20070088051-A1 | INDOLINONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088051-A1 | INDOLINONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | MKI67, CCNT1, CCNA1 | MDM2 491/4885TGM2 4589/4885NPC1 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.